This company has been marked as potentially delisted and may not be actively trading. NASDAQ:NEOS Neos Therapeutics (NEOS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Neos Therapeutics Stock (NASDAQ:NEOS) 30 days 90 days 365 days Advanced Chart Get Neos Therapeutics alerts:Sign Up Key Stats Today's Range$1.06▼$1.1850-Day Range$0.77▼$1.1852-Week Range$0.45▼$1.68Volume15.01 million shsAverage Volume7.44 million shsMarket Capitalization$57.22 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate to treat ADHD; Adzenys ER amphetamine for the treatment of ADHD; and generic Tussionex, a hydrocodone and chlorpheniramine polistirex XR oral suspension for cough and upper respiratory symptoms of a cold. It also offers NT0502, a clinical-stage product candidate that has completed Phase I pilot pharmacokinetic trial for the treatment of neurological conditions associated with excessive salivation and drooling to reduce chronic sialorrhea in patients. The company was incorporated in 2009 and is headquartered in Grand Prairie, Texas. Read More Receive NEOS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NEOS Stock News HeadlinesUSAntibiotics Names Mark Tengler Senior Vice President of Manufacturing TechnologiesMarch 31, 2025 | finance.yahoo.comElement5 transforms prior authorization process, launches new AI Agent solution: NeosJanuary 16, 2025 | finance.yahoo.com“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.September 7 at 2:00 AM | InvestorPlace (Ad)Aytu BioPharma, Inc.: Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial ResultsNovember 13, 2024 | finanznachrichten.deMCET MultiCell Technologies, Inc.October 31, 2024 | seekingalpha.comNEOS/USD - NeosCoin US DollarOctober 18, 2024 | investing.comCara Therapeutics, Inc. (CARA)April 21, 2024 | finance.yahoo.comAvenue Bank wins full APRA licence, bank guarantees in sightMarch 3, 2024 | afr.comSee More Headlines NEOS Stock Analysis - Frequently Asked Questions How were Neos Therapeutics' earnings last quarter? Neos Therapeutics, Inc. (NASDAQ:NEOS) released its quarterly earnings data on Monday, November, 9th. The company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by $0.05. The company had revenue of $12.54 million for the quarter. When did Neos Therapeutics IPO? Neos Therapeutics (NEOS) raised $60 million in an initial public offering on Thursday, July 23rd 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager. What other stocks do shareholders of Neos Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neos Therapeutics investors own include TherapeuticsMD (TXMD), Onconova Therapeutics (ONTX), Adamis Pharmaceuticals (ADMP), Acasti Pharma (ACST), SCYNEXIS (SCYX), Corbus Pharmaceuticals (CRBP) and AVEO Pharmaceuticals (AVEO). Company Calendar Last Earnings11/09/2020Today9/07/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:NEOS CIK1467652 Webwww.neostx.com Phone972-408-1300FaxN/AEmployees213Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$16.90 million Net Margins-38.35% Pretax MarginN/A Return on EquityN/A Return on Assets-28.46% Debt Debt-to-Equity RatioN/A Current Ratio0.66 Quick Ratio0.53 Sales & Book Value Annual Sales$64.65 million Price / Sales0.89 Cash FlowN/A Price / Cash FlowN/A Book Value($0.12) per share Price / Book-9.58Miscellaneous Outstanding Shares49,757,000Free FloatN/AMarket Cap$57.22 million OptionableOptionable Beta1.50 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:NEOS) was last updated on 9/7/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated b...Banyan Hill Publishing | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NEOS Stock Alerts